Quarterly report [Sections 13 or 15(d)]

Acquisition of CorHepta (Additional Information) (Details)

v3.26.3
Acquisition of CorHepta (Additional Information) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Feb. 21, 2026
Feb. 21, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Business Combination [Line Items]            
Shares vested 2,489,545       4,149,252  
Shares Unvested         4,149,252  
Shares forfeited         1,660,222  
Change in fair value contingent consideration   $ 4,435,443 $ 0 $ 492,827 $ 373,354 $ 2,016,111
Written off         $ 7,357,294  
CorHepta Pharmaceuticals [Member]            
Business Combination [Line Items]            
Date of acquisition agreement   Feb. 21, 2025        
Shares representing contingent consideration         1,493,415  
Operating Expenses       $ 492,827   $ 2,016,111
Change in fair value contingent consideration     $ 0   $ 373,354  
Number of Shares, Granted   2,489,030        
Consideration transferred         $ 7,400,000  
CorHepta Pharmaceuticals [Member] | Common Stock            
Business Combination [Line Items]            
Issuance of common stock, Shares   4,979,101        
Shares vested   829,849     829,849  
Shares representing contingent consideration   2,489,030        
Shares representing post-merger compensation expense   1,660,222        
Shares Unvested   1,493,415